ATC code L01

L01AA Nitrogen mustard analogues

 * L01AA01 Cyclophosphamide
 * L01AA02 Chlorambucil
 * L01AA03 Melphalan
 * L01AA05 Chlormethine
 * L01AA06 Ifosfamide
 * L01AA07 Trofosfamide
 * L01AA08 Prednimustine
 * L01AA09 Bendamustine
 * L01AA10 Melphalan flufenamide

L01AB Alkyl sulfonates

 * L01AB01 Busulfan
 * L01AB02 Treosulfan
 * L01AB03 Mannosulfan

L01AC Ethylene imines

 * L01AC01 Thiotepa
 * L01AC02 Triaziquone
 * L01AC03 Carboquone

L01AD Nitrosoureas

 * L01AD01 Carmustine
 * L01AD02 Lomustine
 * L01AD03 Semustine
 * L01AD04 Streptozocin
 * L01AD05 Fotemustine
 * L01AD06 Nimustine
 * L01AD07 Ranimustine
 * L01AD08 Uramustine

L01AG Epoxides

 * L01AG01 Etoglucid

L01AX Other alkylating agents

 * L01AX01 Mitobronitol
 * L01AX02 Pipobroman
 * L01AX03 Temozolomide
 * L01AX04 Dacarbazine

L01BA Folic acid analogues

 * L01BA01 Methotrexate
 * L01BA03 Raltitrexed
 * L01BA04 Pemetrexed
 * L01BA05 Pralatrexate

L01BB Purine analogues

 * L01BB02 Mercaptopurine
 * L01BB03 Tioguanine
 * L01BB04 Cladribine
 * L01BB05 Fludarabine
 * L01BB06 Clofarabine
 * L01BB07 Nelarabine
 * QL01BB90 Rabacfosadine

L01BC Pyrimidine analogues

 * L01BC01 Cytarabine
 * L01BC02 Fluorouracil
 * L01BC03 Tegafur
 * L01BC04 Carmofur
 * L01BC05 Gemcitabine
 * L01BC06 Capecitabine
 * L01BC07 Azacitidine
 * L01BC08 Decitabine
 * L01BC09 Floxuridine
 * L01BC52 Fluorouracil, combinations
 * L01BC53 Tegafur, combinations
 * L01BC58 Decitabine, combinations
 * L01BC59 Trifluridine, combinations

L01CA Vinca alkaloids and analogues

 * L01CA01 Vinblastine
 * L01CA02 Vincristine
 * L01CA03 Vindesine
 * L01CA04 Vinorelbine
 * L01CA05 Vinflunine
 * L01CA06 Vintafolide

L01CB Podophyllotoxin derivatives

 * L01CB01 Etoposide
 * L01CB02 Teniposide

L01CC Colchicine derivatives

 * L01CC01 Demecolcine

L01CD Taxanes

 * L01CD01 Paclitaxel
 * L01CD02 Docetaxel
 * L01CD03 Paclitaxel poliglumex
 * L01CD04 Cabazitaxel
 * L01CD51 Paclitaxel and encequidar

L01CE Topoisomerase 1 (TOP1) inhibitors

 * L01CE01 Topotecan
 * L01CE02 Irinotecan
 * L01CE03 Etirinotecan pegol
 * L01CE04 Belotecan

L01CX Other plant alkaloids and natural products

 * L01CX01 Trabectedin

L01DA Actinomycines

 * L01DA01 Dactinomycin

L01DB Anthracyclines and related substances

 * L01DB01 Doxorubicin
 * L01DB02 Daunorubicin
 * L01DB03 Epirubicin
 * L01DB04 Aclarubicin
 * L01DB05 Zorubicin
 * L01DB06 Idarubicin
 * L01DB07 Mitoxantrone
 * L01DB08 Pirarubicin
 * L01DB09 Valrubicin
 * L01DB10 Amrubicin
 * L01DB11 Pixantrone

L01DC Other cytotoxic antibiotics

 * L01DC01 Bleomycin
 * L01DC02 Plicamycin
 * L01DC03 Mitomycin
 * L01DC04 Ixabepilone

L01EA BCR-ABL tyrosine kinase inhibitors

 * L01EA01 Imatinib
 * L01EA02 Dasatinib
 * L01EA03 Nilotinib
 * L01EA04 Bosutinib
 * L01EA05 Ponatinib
 * L01EA06 Asciminib

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

 * L01EB01 Gefitinib
 * L01EB02 Erlotinib
 * L01EB03 Afatinib
 * L01EB04 Osimertinib
 * L01EB05 Rociletinib
 * L01EB06 Olmutinib
 * L01EB07 Dacomitinib
 * L01EB08 Icotinib
 * L01EB09 Lazertinib
 * L01EB10 Mobocertinib
 * L01EB11 Aumolertinib

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors

 * L01EC01 Vemurafenib
 * L01EC02 Dabrafenib
 * L01EC03 Encorafenib

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

 * L01ED01 Crizotinib
 * L01ED02 Ceritinib
 * L01ED03 Alectinib
 * L01ED04 Brigatinib
 * L01ED05 Lorlatinib

L01EE Mitogen-activated protein kinase (MEK) inhibitors

 * L01EE01 Trametinib
 * L01EE02 Cobimetinib
 * L01EE03 Binimetinib
 * L01EE04 Selumetinib

L01EF Cyclin-dependent kinase (CDK) inhibitors

 * L01EF01 Palbociclib
 * L01EF02 Ribociclib
 * L01EF03 Abemaciclib

L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors

 * L01EG01 Temsirolimus
 * L01EG02 Everolimus
 * L01EG03 Ridaforolimus
 * L01EG04 Sirolimus

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

 * L01EH01 Lapatinib
 * L01EH02 Neratinib
 * L01EH03 Tucatinib

L01EJ Janus-associated kinase (JAK) inhibitors

 * L01EJ01 Ruxolitinib
 * L01EJ02 Fedratinib
 * L01EJ03 Pacritinib
 * L01EJ04 Momelotinib

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

 * L01EK01 Axitinib
 * L01EK02 Cediranib
 * L01EK03 Tivozanib
 * L01EK04 Fruquintinib

L01EL Bruton's tyrosine kinase (BTK) inhibitors

 * L01EL01 Ibrutinib
 * L01EL02 Acalabrutinib
 * L01EL03 Zanubrutinib
 * L01EL04 Orelabrutinib
 * L01EL05 Pirtobrutinib

L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors

 * L01EM01 Idelalisib
 * L01EM02 Copanlisib
 * L01EM03 Alpelisib
 * L01EM04 Duvelisib
 * L01EM05 Parsaclisib

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

 * L01EN01 Erdafitinib
 * L01EN02 Pemigatinib
 * L01EN03 Infigratinib
 * L01EN04 Futibatinib

L01EX Other protein kinase inhibitors

 * L01EX01 Sunitinib
 * L01EX02 Sorafenib
 * L01EX03 Pazopanib
 * L01EX04 Vandetanib
 * L01EX05 Regorafenib
 * L01EX06 Masitinib
 * L01EX07 Cabozantinib
 * L01EX08 Lenvatinib
 * L01EX09 Nintedanib
 * L01EX10 Midostaurin
 * L01EX11 Quizartinib
 * L01EX12 Larotrectinib
 * L01EX13 Gilteritinib
 * L01EX14 Entrectinib
 * L01EX15 Pexidartinib
 * L01EX17 Capmatinib
 * L01EX18 Avapritinib
 * L01EX19 Ripretinib
 * L01EX21 Tepotinib
 * L01EX22 Selpercatinib
 * L01EX23 Pralsetinib
 * L01EX24 Surufatinib
 * L01EX25 Umbralisib
 * L01EX26 Sitravatinib
 * L01EX27 Capivasertib
 * QL01EX90 Toceranib

L01FA CD20 (clusters of differentiation 20) inhibitors

 * L01FA01 Rituximab
 * L01FA02 Ofatumumab
 * L01FA03 Obinutuzumab

L01FB CD22 (clusters of differentiation 22) inhibitors

 * L01FB01 Inotuzumab ozogamicin
 * L01FB02 Moxetumomab pasudotox

L01FC CD38 (clusters of differentiation 38) inhibitors

 * L01FC01 Daratumumab
 * L01FC02 Isatuximab

L01FD HER2 (human epidermal growth factor receptor 2) inhibitors

 * L01FD01 Trastuzumab
 * L01FD02 Pertuzumab
 * L01FD03 Trastuzumab emtansine
 * L01FD04 Trastuzumab deruxtecan
 * L01FD05 Trastuzumab duocarmazine
 * L01FD06 Margetuximab

L01FE EGFR (epidermal growth factor receptor) inhibitors

 * L01FE01 Cetuximab
 * L01FE02 Panitumumab
 * L01FE03 Necitumumab

L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors

 * L01FF01 Nivolumab
 * L01FF02 Pembrolizumab
 * L01FF03 Durvalumab
 * L01FF04 Avelumab
 * L01FF05 Atezolizumab
 * L01FF06 Cemiplimab
 * L01FF07 Dostarlimab
 * L01FF08 Prolgolimab
 * L01FF09 Tislelizumab
 * L01FF10 Retifanlimab
 * L01FF11 Sugemalimab
 * L01FF12 Serplulimab
 * L01FF13 Toripalimab

L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors

 * L01FG01 Bevacizumab
 * L01FG02 Ramucirumab

L01FX Other monoclonal antibodies and antibody drug conjugates

 * L01FX01 Edrecolomab
 * L01FX02 Gemtuzumab ozogamicin
 * L01FX03 Catumaxomab
 * L01FX04 Ipilimumab
 * L01FX05 Brentuximab vedotin
 * L01FX06 Dinutuximab beta
 * L01FX07 Blinatumomab
 * L01FX08 Elotuzumab
 * L01FX09 Mogamulizumab
 * L01FX10 Olaratumab
 * L01FX11 Bermekimab
 * L01FX12 Tafasitamab
 * L01FX13 Enfortumab vedotin
 * L01FX14 Polatuzumab vedotin
 * L01FX15 Belantamab mafodotin
 * L01FX16 Oportuzumab monatox
 * L01FX17 Sacituzumab govitecan
 * L01FX18 Amivantamab
 * L01FX19 Sabatolimab
 * L01FX20 Tremelimumab
 * L01FX21 Naxitamab
 * L01FX22 Loncastuximab tesirine
 * L01FX23 Tisotumab vedotin
 * L01FX24 Teclistamab
 * L01FX25 Mosunetuzumab
 * L01FX26 Mirvetuximab soravtansine
 * L01FX27 Epcoritamab
 * L01FX28 Glofitamab
 * L01FX29 Talquetamab

L01FY Combinations of monoclonal antibodies and antibody drug conjugates

 * L01FY01 Pertuzumab and trastuzumab
 * L01FY02 Nivolumab and relatlimab
 * L01FY03 Prolgolimab and nurulimab

L01XA Platinum compounds

 * L01XA01 Cisplatin
 * L01XA02 Carboplatin
 * L01XA03 Oxaliplatin
 * L01XA04 Satraplatin
 * L01XA05 Polyplatillen

L01XB Methylhydrazines

 * L01XB01 Procarbazine

L01XD Sensitizers used in photodynamic/radiation therapy

 * L01XD01 Porfimer sodium
 * L01XD03 Methyl aminolevulinate
 * L01XD04 Aminolevulinic acid
 * L01XD05 Temoporfin
 * L01XD06 Efaproxiral
 * L01XD07 Padeliporfin

L01XF Retinoids for cancer treatment

 * L01XF01 Tretinoin
 * L01XF02 Alitretinoin
 * L01XF03 Bexarotene

L01XG Proteasome inhibitors

 * L01XG01 Bortezomib
 * L01XG02 Carfilzomib
 * L01XG03 Ixazomib

L01XH Histone deacetylase (HDAC) inhibitors

 * L01XH01 Vorinostat
 * L01XH02 Romidepsin
 * L01XH03 Panobinostat
 * L01XH04 Belinostat
 * L01XH05 Entinostat

L01XJ Hedgehog pathway inhibitors

 * L01XJ01 Vismodegib
 * L01XJ02 Sonidegib
 * L01XJ03 Glasdegib

L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

 * L01XK01 Olaparib
 * L01XK02 Niraparib
 * L01XK03 Rucaparib
 * L01XK04 Talazoparib
 * L01XK05 Veliparib
 * L01XK06 Pamiparib
 * L01XK52 Niraparib and abiraterone

L01XL Antineoplastic cell and gene therapy

 * L01XL01 Sitimagene ceradenovec
 * L01XL02 Talimogene laherparepvec
 * L01XL03 Axicabtagene ciloleucel
 * L01XL04 Tisagenlecleucel
 * L01XL05 Ciltacabtagene autoleucel
 * L01XL06 Brexucabtagene autoleucel
 * L01XL07 Idecabtagene vicleucel
 * L01XL08 Lisocabtagene maraleucel
 * L01XL09 Tabelecleucel
 * L01XL10 Nadofaragene firadenovec
 * L01XL11 Lifileucel

L01XX Other antineoplastic agents

 * L01XX01 Amsacrine
 * L01XX02 Asparaginase
 * L01XX03 Altretamine
 * L01XX05 Hydroxycarbamide
 * L01XX07 Lonidamine
 * L01XX08 Pentostatin
 * L01XX10 Masoprocol
 * L01XX11 Estramustine
 * L01XX16 Mitoguazone
 * L01XX18 Tiazofurine
 * L01XX23 Mitotane
 * L01XX24 Pegaspargase
 * L01XX27 Arsenic trioxide
 * L01XX29 Denileukin diftitox
 * L01XX33 Celecoxib
 * L01XX35 Anagrelide
 * L01XX36 Oblimersen
 * L01XX40 Omacetaxine mepesuccinate
 * L01XX41 Eribulin
 * L01XX44 Aflibercept
 * L01XX46 Olaparib
 * L01XX52 Venetoclax
 * L01XX53 Vosaroxin
 * L01XX57 Plitidepsin
 * L01XX58 Epacadostat
 * L01XX59 Enasidenib
 * L01XX62 Ivosidenib
 * L01XX66 Selinexor
 * L01XX67 Tagraxofusp
 * L01XX69 Lurbinectedin
 * L01XX72 Tazemetostat
 * L01XX73 Sotorasib
 * L01XX74 Belzutifan
 * L01XX75 Tebentafusp
 * L01XX77 Adagrasib
 * L01XX78 Navitoclax
 * L01XX79 Eflornithine
 * L01XX80 Imetelstat
 * QL01XX91 Tigilanol tiglate
 * QL01XX92 Verdinexor

L01XY Combinations of antineoplastic agents

 * L01XY01 Cytarabine and daunorubicin